We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Interest of Relaxation From Patients With Pain Due to Migraine (MIGREL)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00904527
First Posted: May 19, 2009
Last Update Posted: July 28, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Saint Etienne
  Purpose
The purpose of this study is to determine whether relaxation (autogenic training of Schultz) is effective in treatment for migraine.

Condition Intervention
Migraine Behavioral: relaxation (Schultz)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Interest of Relaxation From Patients With Pain Due to Migraine

Resource links provided by NLM:


Further study details as provided by Centre Hospitalier Universitaire de Saint Etienne:

Primary Outcome Measures:
  • Comparison of reduction of migraine frequency between the 2 groups (with or without relaxation) [ Time Frame: 4 months ]

Secondary Outcome Measures:
  • Comparison between the 2 groups of intensity of migraine, medication use and quality of life [ Time Frame: 4 months ]

Enrollment: 60
Study Start Date: June 2006
Study Completion Date: April 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Relaxation
Relaxation (Schultz)+ medical treatment (beta-bloquant or Oxetorone)+ patient's education
Behavioral: relaxation (Schultz)
Patients have relaxation consultations during 2 months
No Intervention: without relaxation
Patients have no relaxation (only medical treatment+ education)

Detailed Description:

This randomized, multicenter study compares 2 parallel groups of patients with migraine :

  • I: patients are treated with relaxation + medical treatment (beta-bloquant or Oxetorone)+ patients' education
  • II: patients are treated only with medical treatment + patients' education.

Visit 1 : 1 month before randomization for patient's selection and baseline data

Visit 2 (J0): inclusion (randomization) During the first 2 months patients from group I benefit from relaxation consultations.

Visit 3 (2 months after randomization)and visit 4 (4 months after randomization) : evaluation of the efficacy of the two treatment strategies.

Primary endpoint :

- number of days with migraine per month from J0 to visit 4.

Secondary endpoints :

  • monthly drug consumption
  • percentage of patients who respond (50 % frequency reduction)
  • quality of life (SF 36)

Each day, patients note in a notebook if a migraine appears and its intensity.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age > 18 years
  • 5 to 14 days of migraines per month

Exclusion Criteria:

  • Headache by medication abuse
  • Patients who already know relaxation technics
  • Depression
  • Contra indication of using beta-bloquant or Oxetorone
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00904527


Locations
France
Consultation de la douleur du CHU d'Amiens
Amiens, France, 80000
UTCD - CHU Pellegrin
Bordeaux, France, 33000
CETD - CHU de Caen
Caen, France, 14033
CETD du CHU Gabriel Montpied
Clermont-Ferrand, France, 63000
CETD CHU de Grenoble
Grenoble, France, 38043
Consultation de la douleur - CH Emile Roux
Le Puy-en Velay, France, 43000
CETD CH de Nemours
Nemours, France, 77140
CETD du CHU de Saint-ETienne
Saint Etienne, France, 42055
CETD Hôpital Rangueil
Toulouse, France, 31403
Sponsors and Collaborators
Centre Hospitalier Universitaire de Saint Etienne
Investigators
Study Director: LAURENT Bernard, MD PhD Centre Hospitalier Universitaire de Saint Etienne
Study Chair: PICKERING Gisèle, MD Centre d'Investigation Clinique de Clermont-Ferrand
  More Information

Responsible Party: Centre Hospitalier Universitaire de Saint Etienne
ClinicalTrials.gov Identifier: NCT00904527     History of Changes
Other Study ID Numbers: 0601001b
First Submitted: May 18, 2009
First Posted: May 19, 2009
Last Update Posted: July 28, 2015
Last Verified: July 2015

Keywords provided by Centre Hospitalier Universitaire de Saint Etienne:
Relaxation (Schultz)
Migraine
antipain center

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases